IL6 and cancer: These results show that the IL-6/IL-6R pathway initiated by PGCCs (induced by paclitaxel), rather than paclitaxel per se or regular cancer cells, plays a key role in the organization and remodeling of collagen I, and this remodeling can be attenuated by blocking IL-6.